Table 4

PSAMRIS for individual MRI features as assessed by PSAMRIS-H and PSAMRIS-F, for both treatment arms, at baseline and change from baseline to week 24

PSAMRIS featuresMCP/MTPPIPDIP
GLM+MTXPLB+MTXGLM+MTXPLB+MTXGLM+MTXPLB+MTX
BaselineChangeBaselineChangeBaselineChangeBaselineChangeBaselineChangeBaselineChange
Synovitis, mean3.8−2.873.44−1.941.93−1.54*1.0601−0.671−0.71
(observed range)(0 to 12)(−9 to 0)(0 to 7)(−7 to 2)(0 to 4)(−4 to 1)(0 to 3)(−3 to 3)(0 to 3)(−2 to 0)(0 to 4)(-2 to 0)
Flexor tenosynovitis, mean0.56−0.380.47−0.050.56−0.380.47−0.051.4−11−0.33
(observed range)(0 to 3)(−2 to 0)(0 to 3)(−2 to 2)(0 to 3)(−2 to 0)(0 to 3)(−2 to 2)(0 to 3)(−2 to 0)(0 to 3)(-2 to 2)
Periarticular inflammation, mean3.14−1.863−2.410.3300.330.140.6−0.40.5−0.29
(observed range)(0 to 24)(−14 to 0)(0 to 7)(−7 to 0)(0 to 2)(0 to 0)(0 to 2)(0 to 1)(0 to 2)(−1 to 0)(0 to 2)(-1 to 0)
Bone marrow oedema, mean4.56−2.943.11−2.674.82−3.593−0.721.33−12-1
(observed range)(0 to 23)(−14 to 0)(0 to 16)(−16 to 0)(0 to 24)(−22 to 1)(0 to 16)(−8 to 4)(0 to 6)(−6 to 0)(0 to 8)(-4 to 0)
Bone erosion, mean2.060.51.47−0.061.4701.530.896.3302.890
(observed range)(0 to 12)(−3 to 12)(0 to 8)(−2 to 1)(0 to 13)(0 to 0)(0 to 14)(−1 to 10)(0 to 14)(0 to 0)(0 to 8)(0 to 0)
Bone proliferation, mean2.8301.6702.6702.6702.2−0.820
(observed range)(0 to 5)(0 to 0)(0 to 5)(0 to 0)(0 to 5)(0 to 0)(0 to 5)(0 to 0)(0 to 4)(−4 to 0)(0 to 4)(0 to 0)
  • *Difference between treatment groups in the change from baseline to week 24 (p=0.0054); p<0.05.

  • DIP, distal interphalangeal joints; GLM, golimumab; MCP/MTP, metacarpal/metatarsophalangeal joints; MTX, methotrexate; PIP, proximal interphalangeal joints; PLB, placebo; PSAMRIS, Psoriatic Arthritis MRI Score; PSAMRIS-F, Psoriatic Arthritis MRI Score for the foot.; PSAMRIS-H, Psoriatic Arthritis MRI Score for the hand.